# HIV Immune and Virological Responses Following the Administration of IL-2 Either Alone or Combined to ALVAC-HIV 1433 and HIV Lipopeptides in Patients Treated Early With HAART During Primary Infection

> **NCT00196651** · PHASE2 · TERMINATED · sponsor: **French National Agency for Research on AIDS and Viral Hepatitis** · enrollment: 60 (—)

## Conditions studied

- HIV Infection

## Interventions

- **DRUG:** IL-2
- **BIOLOGICAL:** LIPO-6T
- **BIOLOGICAL:** ALVAC VIH 1433

## Key facts

- **NCT ID:** NCT00196651
- **Lead sponsor:** French National Agency for Research on AIDS and Viral Hepatitis
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2000-08
- **Primary completion:** —
- **Final completion:** 2004-02
- **Target enrollment:** 60 (—)
- **Last updated:** 2005-09-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00196651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00196651, "HIV Immune and Virological Responses Following the Administration of IL-2 Either Alone or Combined to ALVAC-HIV 1433 and HIV Lipopeptides in Patients Treated Early With HAART During Primary Infection". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00196651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*